Drug interactions
Lapatinib + Tafamidis meglumine
Severity: Minor
Lapatinib and Tafamidis meglumine: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Tafamidis meglumine inhibits BCRP in vitro, and lapatinib is a BCRP substrate. Lapatinib exposure may rise and increase its adverse effects.
What this interaction means in plain words
Lapatinib and Tafamidis meglumine have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
Tafamidis inhibits BCRP efflux transport, potentially increasing lapatinib exposure.
What to do
Monitor for lapatinib toxicity such as diarrhea, rash and liver enzyme changes. Adjust the lapatinib dose only if adverse effects occur.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lapatinib and Tafamidis meglumine, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Lapatinib
- Dofetilide + Lapatinib Contraindicated
- Ibutilide + Lapatinib Contraindicated
- Lapatinib + Pimozide Contraindicated
- Lapatinib + Saquinavir Contraindicated
- Lapatinib + Thioridazine Contraindicated
- Adagrasib + Lapatinib Major
Frequently asked questions
Can I take Lapatinib with Tafamidis meglumine?
MediHelp rates the interaction as minor. Lapatinib and Tafamidis meglumine have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Tafamidis meglumine inhibits BCRP in vitro, and lapatinib is a BCRP substrate. Lapatinib exposure may rise and increase its adverse effects.
How serious is the interaction between Lapatinib and Tafamidis meglumine?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for lapatinib toxicity such as diarrhea, rash and liver enzyme changes. Adjust the lapatinib dose only if adverse effects occur.
What other medicines interact with Lapatinib?
MediHelp also lists interactions of Lapatinib with, for example, Dofetilide, Ibutilide, Pimozide. The full list is on the Lapatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
